As we expected, the therapeutic effect was more significant in the group treated with Smad7-MSCs comparing with the group treated with MSCs alone, suggesting that MSCs overexpressing Smad7 are more effective in the treatment of liver cirrhosis via inhibiting TGF-β1-Smad signalling pathway. This evidence concerns the gene TGFB1 and cirrhosis of liver.